Escitalopram: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Howard C. Berkowitz
No edit summary
Line 1: Line 1:
{{subpages}}
{{subpages}}
{{TOC|right}}
{{TOC|right}}
In [[psychiatry]], '''escitalopram''' is a [[second-generation antidepressant]] for treating [[major depressive disorder]]. Escitalopram      is the S-enantiomer of racemic [[citalopram]].<ref name="pmid19370639">{{cite journal| author=Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al.| title=Escitalopram versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2009 | volume=  | issue= 2 | pages= CD006532 | pmid=19370639  
In [[psychiatry]], '''escitalopram''' is a [[second-generation antidepressant]] for treating [[major depressive disorder]]. It is also effective in reducing [[ethanol]] uptake in [[alcoholism|alcoholics]] and is used in depressed patients who also suffer from [[tardive dyskinesia]] in preference to [[tricyclic antidepressant]]s, which aggravate this condition. <ref> {{MeSH}}</ref>
 
Escitalopram      is the S-enantiomer of racemic [[citalopram]].<ref name="pmid19370639">{{cite journal| author=Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al.| title=Escitalopram versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2009 | volume=  | issue= 2 | pages= CD006532 | pmid=19370639  
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19370639 | doi=10.1002/14651858.CD006532.pub2 }} </ref>
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19370639 | doi=10.1002/14651858.CD006532.pub2 }} </ref>
==History==
==History==

Revision as of 10:11, 17 April 2010

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In psychiatry, escitalopram is a second-generation antidepressant for treating major depressive disorder. It is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition. [1]

Escitalopram is the S-enantiomer of racemic citalopram.[2]

History

Lexapro brand of escitalopram was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 2002.[3]

Efficacy

According to a systematic review by the Cochrane Collaboration:[2]

"Some statistically significant differences favouring escitalopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxetine). There is insufficient evidence to detect a difference between escitalopram and other antidepressants in early response to treatment (after two weeks of treatment). Cost-effectiveness information is also needed in the field of antidepressant trials. Furthermore, as with most standard systematic reviews, the findings rely on evidence from direct comparisons. The potential for overestimation of treatment effect due to sponsorship bias should also be borne in mind."

External links

The most up-to-date information about Escitalopram and other drugs can be found at the following sites.


References

  1. Anonymous (2024), Escitalopram (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al. (2009). "Escitalopram versus other antidepressive agents for depression.". Cochrane Database Syst Rev (2): CD006532. DOI:10.1002/14651858.CD006532.pub2. PMID 19370639. Research Blogging.
  3. Drugs@FDA.